Nordea sees increasing tailwind for Genmab
Strong clinical data and a recent submission of an application to the FDA have Nordea believing Genmab will be propelled to the same heights as a successful US-based biotech rival.
BY STEFAN SINGH KAILAY
Denmark’s Genmab is enjoying a great spell at the Copenhagen Stock Exchange at the moment, but the biotech company could be heading for even greener pastures, according to Nordea which points to two factors in Thursday’s morning report and likens the group to US-based peer Pharmacyclics.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Genmab hope could hit the market this year
For abonnenter
Nordea: Analysts overlook daratumumab’s potential
For abonnenter
Genmab buys antibodies from BMS
For abonnenter
